Rutgers, the State University of New Jersey

Collaborations Pharmaceuticals, Inc.

Johns Hopkins University

The Lundquist Institute for Biomedical Innovation at Harbor-ucla Medical Center

Universitatsklinikum Jena

Sean Ekins

Joel S Freundlich

David Alland

Divya Awasthi

Matthew B Neiditch

Pradeep Kumar

Glenn Capodagli

Craig Arthur Townsend

Gyanu Lamichhane

Vadim Albertovich Makarov

Nicole M Parrish

Michaela Schmidtke

Evan P Lloyd

Ana C Puhl Rubio

Julia Chung

Thomas R Lane

Amit Kaushik

Pankaj Kumar

Aaron McMurtray

Natalie Diaz

Shaogang Li

The invention provides compounds of formula I: and salts thereof wherein R-Rhave any of the meanings described in the specification. The compounds are useful for treating bacterial infections (e.g. tuberculosis).

Therapeutic indazoles

Methods of treating or preventing diseases caused by viral infections via the administration of pyronaridine, quinacrine, and/or tilorone are described. The viral infections can be caused by viruses such as Marburg virus (MARV), Chikungunya virus (CHIKV), norovirus, Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Nipah virus.

Use of pyronaridine, tilorone, and quinacrine against Marburg virus and other virus infections

Methods of modulating the interaction between &#x3b2;-amyloid and &#x3b1;7-nAChR are provided. Aspects of the methods include administering to the subject an effective amount of a naphthalene derivative active agent. Compositions and kits for practicing the subject methods are also provided. The methods, compositions and kits find use in treating a variety of applications, such as treating a subject for a neurodegenerative disease, e.g., Alzheimer's disease.

Methods and compositions for modulating &#x3b2;-amyloid/&#x3b1;7-nAChR interactions

The invention provides compounds of formula (I): and salts thereof wherein R-Rhave any of the meanings described in the specification. The compounds are useful for treating bacterial infections (e.g. tuberculosis). 

New antimicrobials targeting L,D-transpeptidases, non-classical cysteine peptidases, have been developed and their unique chemical structures identified. Carbapenems and penems of the present invention are unique among &#x3b2;-lactams as they acylate and inhibit L,D-transpeptidases, which likely results in their superior antimicrobial potency. These new antimicrobial agents can be used alone, or in combination with other classic antimicrobial agents that target D,D transpeptidases, when treating bacterial infections.

Inhibitors of bacterial growth

Growing community of inventors

Fuquay Varina, NC, United States of America

Sean Ekins